Crossject Société Anonyme develops needle-free injection systems. More Details
+ 1 more risk
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Crossject Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALCJ's share price has been volatile over the past 3 months.
7 Day Return
FR Medical Equipment
1 Year Return
FR Medical Equipment
Return vs Industry: ALCJ exceeded the French Medical Equipment industry which returned 56.1% over the past year.
Return vs Market: ALCJ exceeded the French Market which returned -7.2% over the past year.
Price Volatility Vs. Market
How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIf You Had Bought Crossject Société Anonyme (EPA:ALCJ) Stock A Year Ago, You Could Pocket A 136% Gain Today
5 months ago | Simply Wall StDoes Crossject Société Anonyme (EPA:ALCJ) Have A Healthy Balance Sheet?
9 months ago | Simply Wall StSome Crossject Société Anonyme (EPA:ALCJ) Shareholders Have Taken A Painful 77% Share Price Drop
Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALCJ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALCJ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALCJ is unprofitable, so we can't compare its PE Ratio to the FR Medical Equipment industry average.
PE vs Market: ALCJ is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALCJ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALCJ is overvalued based on its PB Ratio (19.9x) compared to the FR Medical Equipment industry average (3.2x).
How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ALCJ's forecast earnings growth is above the savings rate (0.6%).
Earnings vs Market: Insufficient data to determine if ALCJ's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ALCJ's revenue is forecast to grow faster than the French market.
High Growth Revenue: Insufficient data to determine if ALCJ's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALCJ's Return on Equity is forecast to be high in 3 years time
How has Crossject Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALCJ is currently unprofitable.
Growing Profit Margin: ALCJ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALCJ is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare ALCJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALCJ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-5.3%).
Return on Equity
High ROE: ALCJ has a negative Return on Equity (-238.02%), as it is currently unprofitable.
How is Crossject Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALCJ's short term assets (€11.8M) exceed its short term liabilities (€5.2M).
Long Term Liabilities: ALCJ's short term assets (€11.8M) do not cover its long term liabilities (€16.2M).
Debt to Equity History and Analysis
Debt Level: ALCJ's debt to equity ratio (348.3%) is considered high.
Reducing Debt: Insufficient data to determine if ALCJ's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALCJ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALCJ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.9% each year
What is Crossject Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALCJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALCJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALCJ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALCJ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALCJ's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...
|Chairman of Supervisory Board||no data||no data||no data|
|Member of Supervisory Board||no data||no data||no data|
|Independent Vice Chairman of the Supervisory Board||8.67yrs||no data||no data|
|Member of Supervisory Board||1yr||no data||no data|
|Member of Supervisory Board||2yrs||no data||no data|
Experienced Board: ALCJ's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.
Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Crossject Société Anonyme
- Ticker: ALCJ
- Exchange: ENXTPA
- Founded: 1997
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €76.082m
- Shares outstanding: 25.36m
- Website: https://www.crossject.com
Number of Employees
- Crossject Société Anonyme
- 6 Rue Pauline Kergomard
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALCJ||ENXTPA (Euronext Paris)||Yes||Common Stock||FR||EUR||Feb 2014|
|74C||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
|CRJT.F||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Feb 2014|
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/19 04:44|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.